EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Advancing Immunotherapy in Chronic Lymphocytic Leukemia

Krzysztof Bieliński iD, Agnieszka Wysocka, Dawid Tyrna, Tadeusz Robak iD, Bartosz Puła

International Journal of Molecular Sciences · 22.04.2026 · 27 (9) · 3722

DOI: 10.3390/ijms27093722 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 22.04.2026. Verfasst von Krzysztof Bieliński und 4 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Immunotherapy. Die Arbeit nennt 150 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The treatment of chronic lymphocytic leukemia (CLL) has significantly shifted from chemoimmunotherapy to targeted therapies like Bruton’s tyrosine kinase and BCL2 inhibitors. Despite these advancements, CLL remains an incurable disease characterized by immune dysregulation, therapeutic resistance, and cumulative toxicities. To overcome these challenges, novel immunotherapeutic strategies are emerging as fundamentally different approaches that target immune–tumor interactions. These innovations include novel monoclonal antibodies, bispecific antibodies that redirect T cell cytotoxicity, chimeric antigen receptor (CAR) T-cell therapies, and natural killer (NK) cell-based platforms. By actively engaging cellular cytotoxicity, these approaches show promise in high-risk and treatment-resistant scenarios where standard pathway inhibition is inadequate. Establishing optimal use, toxicity management, and combination strategies for these cell-engaging immunotherapies is now a critical priority in contemporary CLL research.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Leukemia, Lymphocytic, Chronic, B-CellImmunotherapyHumansAntibodies, BispecificAntibodies, MonoclonalKiller Cells, NaturalReceptors, Chimeric AntigenAnimalsImmunotherapy, AdoptiveT-Lymphocytes

Stichwörter der Autor:innen

bispecific antibodieschimeric antigen receptor T cellschronic lymphocytic leukemiaimmunotherapymonoclonal antibodies

Substanzen

Antibodies, BispecificAntibodies, MonoclonalReceptors, Chimeric Antigen

Autor:innen und Institutionen

  • Faculty of Medicine, Medical University of Warsaw, 02-091 Warsaw, Poland.
  • Department of General Hematology and Internal Medicine, Copernicus Memorial Hospital, 93-513 Lodz, Poland.
  • Department of Hematology, Medical University of Lodz, Pabianicka 62 St., 93-513 Lodz, Poland.

ORCID-Profile: Krzysztof Bieliński, Tadeusz Robak

Zitieren

APA

Bieliński, K., Wysocka, A., Tyrna, D., Robak, T., & Puła, B. (2026). Advancing Immunotherapy in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences, 27(9), 3722. https://doi.org/10.3390/ijms27093722

Vancouver

Bieliński K, Wysocka A, Tyrna D, Robak T, Puła B. Advancing Immunotherapy in Chronic Lymphocytic Leukemia. International Journal of Molecular Sciences. 2026;27(9):3722. doi:10.3390/ijms27093722

BibTeX
@article{Bieliski2026,
  author = {Bieliński, Krzysztof and Wysocka, Agnieszka and Tyrna, Dawid and Robak, Tadeusz and Puła, Bartosz},
  title = {Advancing Immunotherapy in Chronic Lymphocytic Leukemia},
  journal = {International Journal of Molecular Sciences},
  year = {2026},
  volume = {27},
  number = {9},
  pages = {3722},
  doi = {10.3390/ijms27093722}
}
Kostenlos starten →